Skip to main content

Beneficial ownership — 13D / 13G

87,240 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Morris Bawabeh LEU Centrus Energy Corp 13D/A 8.8% 2y
Rachel McMinn, Ph.D. NGNE Neurogene Inc. 13D 9.9% 2y
James A. Cacioppo JUSH Jushi Holdings Inc. 13D/A 18.75% 2y
Forager Fund, L.P. DLA Delta Apparel Inc. 13D/A 6.8% 2y
Shareholders affiliated with James R. Scott FIBK First Interstate Bancsystem Inc 13D/A 4.19% 2y
Metal One Corporation FRD Friedman Industries Inc 13G/A 0% 2y
ADAGE CAPITAL PARTNERS GP, L.L.C. HOWL Werewolf Therapeutics, Inc. 13G 8.38% 2y
John K. Scott, Jr. NAVB Navidea Biopharmaceuticals Inc. 13D/A 61.8% 2y
Streeterville Management LLC CAN Canaan Inc. 13G 9.99% 2y
ASP BB HOLDINGS LLC BLBD Blue Bird Corp 13D/A 12.6% 2y
Blackstone Holdings II L.P. ALIT Alight, Inc. / Delaware 13D/A 6.24% 2y
Saba Capital Management, L.P. DMA Destra Multi-Alternative Fund 13D/A 12.56% 2y
BAKER BROS. ADVISORS LP NGNE Neurogene Inc. 13D/A 4.99% 2y
Pittman Scott M. AURX Nuo Therapeutics, Inc. 13D/A 12.1% 2y
Firment Shipping Inc. GLBS Globus Maritime Ltd 13D/A 23.5% 2y
Jeffrey A. Ferrell BIOR Biora Therapeutics, Inc. Common Stock 13D/A 49.9% 2y
CYVN Investments RSC Ltd NIO NIO Inc. 13D/A 7.6% 2y
BIOTECHNOLOGY VALUE FUND L P PNT POINT Biopharma Global Inc. Common Stock 13D/A 0% 2y
REH Company DINO HF Sinclair Corp 13D/A 14% 2y
Charles S. Leykum RNGR Ranger Energy Services, Inc. 13D/A 16.6% 2y
BIOTECHNOLOGY VALUE FUND L P GPCR Structure Therapeutics Inc. 13G/A 1.8% 2y
Wojciech Hlibowicki RUM RUM Group Inc. 13D/A 5.5% 2y
Michael A. Davis (“Davis”) CYAN Cyanotech Corp 13D/A 19.7% 2y
Barry J. Renbaum FMFG Farmers & Merchants Bancshares, Inc. 13D/A 9.9% 2y
Brandon Alexandroff RUM RUM Group Inc. 13D/A 6.7% 2y
IAF, LLC ERNA Ernexa Therapeutics Inc. 13G 9.99% 2y
G&C International Investment Co., Ltd. No I.R.S Identification Number DAZSF ZKGC New Energy Ltd 13D/A 56.35% 2y
LSV Associates, LLC ALXO Alx Oncology Holdings Inc 13D/A 8.4% 2y
Irenic Capital Management LP RSVR Reservoir Media, Inc. 13D 5.1% 2y
Cleveland Avenue Food and Beverage Fund II, LP PRST Presto Technologies, Inc. Common Stock 13D/A 17.1% 2y
Ionic Ventures, LLC BBLG Bone Biologics Corp 13G/A 9.99% 2y
210 Capital, LLC RPC Ridgepost Capital, Inc. 13D 20.9% 2y
Nistec Golan Ltd. ELTK Eltek Ltd 13D/A 62.72% 2y
Coliseum Capital Management, LLC UTI Universal Technical Institute Inc 13D/A 24.9% 2y
Exor N.V. CLVT Clarivate PLC 13D/A 9.62% 2y
Warren B. Kanders CLAR Clarus Corp 13D/A 15.4% 2y
Craig J. Duchossois CHDN Churchill Downs Inc 13D/A 4.4% 2y
Mudrick Capital Management, L.P. GETR Getaround, Inc. 13D/A 23.3% 2y
BIOTECHNOLOGY VALUE FUND L P ACIU AC Immune SA 13G/A 14.8% 2y
Abdiel Qualified Master Fund, LP CRCT Cricut, Inc. 13G 17.9% 2y
Alibaba Group Holding Ltd XPEV Xpeng Inc. 13D/A 9.2% 2y
Green Equity Investors CF, L.P. ASLE AerSale Corp 13D/A 18.6% 2y
Mill Road Capital III, L.P. CULP Culp Inc 13D/A 4.7% 2y
Daniel R. Revers OPAL OPAL Fuels Inc. 13D/A 1.4% 2y
Rolf Schrömgens TRVG trivago N.V. 13D/A 18.2% 2y
Nierenberg Investment Management Company, LLC FTK Flotek Industries Inc 13D/A 4.4% 2y
MCI Capital, LC SRT Startek Inc. 13D/A 7.56% 2y
Phoenix Financial Ltd. KMDA Kamada Ltd 13G/A 4.16% 2y
Sangwoo Park NKGN NKGen Biotech, Inc. Common Stock 13D/A 53.18% 2y
Braden Ferrari BTLN Brightline Interactive, Inc. 13G/A 5.19% 2y